Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citationPrevalence of Diabetic Retinopathy in the United States, 2005-2008
Zhang, X., Saaddine, J. B., Chou, C.-F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., Gregg, E. W., Albright, A. L., Klein, B. E. K., & Klein, R. (2010) · JAMA · doi:10.1001/jama.2010.1111 · Cited by 1,196 · cited 1×
“…key points regarding the major risk factors for DR: First, we con fi rm the importance of the three major risk factors for DR d diabetes duration (17,19,28), HbA 1c (17,28 – 32), and blood pressure (17,28,33) d and suggest that they apply broadly across the mild to vision-threatening stages of DR.”
Self-citationThe Prevalence of Diabetic Retinopathy Among Adults in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.552 · Cited by 1,148
Self-citationKeech, A., Mitchell, P., Summanen, P., O'Day, J., Davis, T., Moffitt, M., Taskinen, M.-R., Simes, R., Tse, D., Williamson, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61607-9 · Cited by 1,109
Self-citationThe Wisconsin Epidemiologic Study of Diabetic Retinopathy
Klein, R., Klein, B. E. K., Moss, S. E., Davis, M. D., & DeMets, D. L. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34102-1 · Cited by 981
Self-citationOverview of Epidemiologic Studies of Diabetic Retinopathy
Kobrin Klein, B. E. (2007) · Ophthalmic Epidemiology · doi:10.1080/09286580701396720 · Cited by 734 · cited 1×
“iabetic retinopathy (DR) is the lead- ingcauseofblindnessamongworking-agedadultsaroundtheworld(1). the signi fi cance of this problem, and the rising prevalence of diabetes notably in emerging Asian countries such as India and China (2,3), there are few precise contemporary estimates of the…”
Self-citationDiabetic Retinopathy in a Multi-ethnic Cohort in the United States
Wong, T. Y., Klein, R., Islam, F. M. A., Cotch, M. F., Folsom, A. R., Klein, B. E. K., Sharrett, A. R., & Shea, S. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.08.063 · Cited by 684 · cited 3×
“In some studies (5), after adjusting for putative DR risk factors, racial differences in the prevalence of DR was attributed to differing levels of risk factors for DR, but in others, the excess risk was unexplained (22,23,25).”
InfluentialSelf-citationHayreh, S. S. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.002 · Cited by 656
Glycosylated Hemoglobin Predicts the Incidence and Progression of Diabetic Retinopathy
Klein, R. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410190112033 · Cited by 529
Self-citationRema, M., Premkumar, S., Anitha, B., Deepa, R., Pradeepa, R., & Mohan, V. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0019 · Cited by 520
Self-citationThe Prevalence of and Factors Associated With Diabetic Retinopathy in the Australian Population
Tapp, R. J., Shaw, J. E., Harper, C. A., de Courten, M. P., Balkau, B., McCarty, D. J., Taylor, H. R., Welborn, T. A., Zimmet, P. Z., & on behalf of the AusDiab Study Group (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1731 · Cited by 439
Self-citationHarris, M. I., Klein, R., Cowie, C. C., Rowland, M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1230 · Cited by 401 · cited 1×
“In some studies (5), after adjusting for putative DR risk factors, racial differences in the prevalence of DR was attributed to differing levels of risk factors for DR, but in others, the excess risk was unexplained (22,23,25).”
Self-citationPrevalence and Risk Factors for Diabetic Retinopathy
Wong, T. Y., Cheung, N., Tay, W. T., Wang, J. J., Aung, T., Saw, S. M., Lim, S. C., Tai, E. S., & Mitchell, P. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.014 · Cited by 400 · cited 2×
“Second, we establish that higher total serum cholesterol was associated with a higher prevalence of DME, bringing clarity to previously conflicting reports about this risk factor (19).”
Self-citationPrevalence of Diabetic Retinopathy in Rural China: The Handan Eye Study
Wang, F. H., Liang, Y. B., Zhang, F., Wang, J. J., Wei, W. B., Tao, Q. S., Sun, L. P., Friedman, D. S., Wang, N. L., & Wong, T. Y. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.003 · Cited by 236
Self-citationPrevalence of diabetic retinopathy in adult Latinos
Varma, R., Torres, M., Peña, F., Klein, R., & Azen, S. P. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.03.002 · Cited by 224
Self-citationRates of Progression in Diabetic Retinopathy During Different Time Periods
Wong, T. Y., Mwamburi, M., Klein, R., Larsen, M., Flynn, H., Hernandez-Medina, M., Ranganathan, G., Wirostko, B., Pleil, A., & Mitchell, P. (2009) · Diabetes Care · doi:10.2337/dc09-0615 · Cited by 206 · cited 1×
“Improvements in the management of DR and diabetes, and increased screening for diabetes, may have led to lower DR incidence and prevalence over time (21).”
Self-citationPrevalence of diabetic retinopathy in an older community
Mitchell, P., Smith, W., Wang, J. J., & Attebo, K. (1998) · Ophthalmology · doi:10.1016/s0161-6420(98)93019-6 · Cited by 203
Self-citationDiabetic Retinopathy in Mexican Americans and Non-Hispanic Whites
Haffner, S. M., Fong, D., Stern, M. P., Pugh, J. A., Hazuda, H. P., Patterson, J. K., Van Heuven, W. A. J., & Klein, R. (1988) · Diabetes · doi:10.2337/diab.37.7.878 · Cited by 201
Self-citationThe Prevalence of Diabetic Retinopathy Among Adult Type1 Diabetic Persons in the United States
Roy, M. S. (2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.546 · Cited by 191 · cited 3×
“Published estimates for VTDR prevalence (17 – 20), for example, ranges widely, from 1.2 (17) to 32.2% (18).”
InfluentialSelf-citationDiabetic retinopathy in Victoria, Australia: the Visual Impairment Project
McKay, R. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.8.865 · Cited by 161
Diabetes and Diabetic Retinopathy in a Mexican-American Population
West, S. K., Klein, R., Rodriguez, J., Muñoz, B., Broman, A. T., Sanchez, R., & Snyder, R. (2001) · Diabetes Care · doi:10.2337/diacare.24.7.1204 · Cited by 160
Self-citation3. Sampling variance of standardized mortality rates.
Keyfitz, N. (1966) · PubMed · Cited by 149
Hamman, R. F., Mayer, E. J., Moo-Young, G. A., Hildebrandt, W., Marshall, J. A., & Baxter, J. (1989) · Diabetes · doi:10.2337/diab.38.10.1231 · Cited by 129
Self-citationThe Role of Genetics in Susceptibility to Diabetic Retinopathy
Liew, G., Klein, R., & Wong, T. Y. (2009) · International Ophthalmology Clinics · doi:10.1097/iio.0b013e31819fd5d7 · Cited by 107 · cited 1×
“Differences in socioeconomic factors, including access to and the level of diabetes care, and possibly genetic susceptibility (26), may also possibly explain some of the disparities in rates and severity of DR in the different ethnic groups.”
Self-citationDiabetic Retinopathy in African Americans With Type 1 Diabetes: The New Jersey 725: II. Risk Factors
Roy, M. S. (2000) · Archives of Ophthalmology · doi:10.1001/archopht.118.1.105 · Cited by 72 · cited 1×
“…key points regarding the major risk factors for DR: First, we con fi rm the importance of the three major risk factors for DR d diabetes duration (17,19,28), HbA 1c (17,28 – 32), and blood pressure (17,28,33) d and suggest that they apply broadly across the mild to vision-threatening stages of DR.”
Self-citationRoy, M. S. (2000) · PubMed · doi:10.1001/archopht.118.1.97 · Cited by 71 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationHarris, E. L., Feldman, S., Robinson, C. R., Sherman, S. I., & Georgopoulos, A. (1993) · Diabetes Care · doi:10.2337/diacare.16.5.748 · Cited by 54
Is there an ethnic difference in the effect of risk factors for diabetic retinopathy?
Haffner, S. M., Mitchell, B. D., Moss, S. E., Stern, M. P., Hazuda, H. P., Patterson, J. K., van Heuven, W. A. J., & Klein, R. (1993) · Annals of Epidemiology · doi:10.1016/1047-2797(93)90003-m · Cited by 40 · cited 3×
“In some studies (5), after adjusting for putative DR risk factors, racial differences in the prevalence of DR was attributed to differing levels of risk factors for DR, but in others, the excess risk was unexplained (22,23,25).”
Self-citation
Cited by
Flaxman, S. R., Bourne, R. R. A., Resnikoff, S., Ackland, P., Braithwaite, T., Cicinelli, M. V., Das, A., Jonas, J. B., Keeffe, J., Kempen, J. H., et al. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30393-5 · Cited by 3,477
Self-citationSteinmetz, J. D., Bourne, R. R. A., Briant, P. S., Flaxman, S. R., Taylor, H. R. B., Jonas, J. B., Abdoli, A. A., Abrha, W. A., Abualhasan, A., Abu-Gharbieh, E. G., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30489-7 · Cited by 3,189
Self-citationPrevalence and Control of Diabetes in Chinese Adults
Xu, Y. (2013) · JAMA · doi:10.1001/jama.2013.168118 · Cited by 2,703
Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045
Teo, Z. L., Tham, Y.-C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y., Lu, Y., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.027 · Cited by 2,420
Self-citationTing, D. S. W., Cheung, C. Y.-L., Lim, G., Tan, G. S. W., Quang, N. D., Gan, A., Hamzah, H., Garcia-Franco, R., San Yeo, I. Y., Lee, S. Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.18152 · Cited by 2,402
“Next, the following subsidiary analyses were performed: (1) the analyses were repeated excluding patients who appeared in both the SIDRP 2010-2013 training set and the primary validation set of SIDRP 2014-2015 (n = 6291 seen more than once in SIDRP), with the patient treated as having referable diabetic retinopathy if…”
MethodSelf-citation
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.